Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis
- PMID: 19478213
- PMCID: PMC2725521
- DOI: 10.1161/STROKEAHA.109.552547
Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis
Abstract
Background and purpose: The Third European Cooperative Acute Stroke Study (ECASS-3) demonstrated a benefit of treatment with intravenous tissue plasminogen activator (tPA) for acute stroke in the 3- to 4.5-hour time-window. Prior studies, however, have failed to demonstrate a significant benefit of tPA for patients treated beyond 3 hours. The purpose of this study was to produce reliable and precise estimates of the treatment effect of tPA by pooling data from all relevant studies.
Methods: A metaanalysis was undertaken to determine the efficacy of tPA in the 3- to 4.5-hour time-window. The effect of tPA on favorable outcome and mortality was assessed.
Results: The metaanalysis included data from patients treated in the 3- to 4.5-hour time-window in ECASS-1 (n=234), ECASS-2 (n=265), ECASS-3 (n=821) and The Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) (n=302). tPA treatment was associated with an increased chance of favorable outcome (odds ratio 1.31; 95% CI: 1.10 to 1.56; P=0.002) and no significant difference in mortality (odds ratio 1.04; 95% CI: 0.75 to 1.43; P=0.83) compared to placebo treated patients.
Conclusions: Treatment with tPA in the 3- to 4.5-hour time-window is beneficial. It results in an increased rate of favorable outcome without adversely affecting mortality.
Conflict of interest statement
Figures

Similar articles
-
Role of tissue plasminogen activator in acute ischemic stroke.Ann Pharmacother. 2011 Mar;45(3):364-71. doi: 10.1345/aph.1P525. Epub 2011 Mar 8. Ann Pharmacother. 2011. PMID: 21386027 Review.
-
Use of tissue-type plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke.Circ Cardiovasc Qual Outcomes. 2012 May;5(3):321-6. doi: 10.1161/CIRCOUTCOMES.111.964064. Epub 2012 May 1. Circ Cardiovasc Qual Outcomes. 2012. PMID: 22550132
-
Impact of the extended thrombolysis time window on the proportion of recombinant tissue-type plasminogen activator-treated stroke patients and on door-to-needle time.Stroke. 2011 Oct;42(10):2838-43. doi: 10.1161/STROKEAHA.111.616565. Epub 2011 Aug 18. Stroke. 2011. PMID: 21852612
-
Optimizing the management of acute ischaemic stroke: a review of the utilization of intravenous recombinant tissue plasminogen activator (tPA).J Clin Pharm Ther. 2012 Dec;37(6):620-9. doi: 10.1111/j.1365-2710.2012.01366.x. Epub 2012 Jun 19. J Clin Pharm Ther. 2012. PMID: 22708668 Review.
-
Transition of European Cooperative Acute Stroke Study III results to clinical practice: ninety-day outcomes in a US cohort.Stroke. 2013 Dec;44(12):3544-6. doi: 10.1161/STROKEAHA.113.002478. Epub 2013 Oct 3. Stroke. 2013. PMID: 24092551
Cited by
-
Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator.Neurocrit Care. 2012 Aug;17(1):107-11. doi: 10.1007/s12028-012-9681-5. Neurocrit Care. 2012. PMID: 22311234
-
Update on the Serum Biomarkers and Genetic Factors Associated with Safety and Efficacy of rt-PA Treatment in Acute Stroke Patients.Stroke Res Treat. 2011;2011:182783. doi: 10.4061/2011/182783. Epub 2011 Jun 9. Stroke Res Treat. 2011. PMID: 21772966 Free PMC article.
-
Induced pluripotent stem cells can improve thrombolytic effect of low-dose rt-PA after acute carotid thrombosis in rat.Stem Cell Res Ther. 2021 Oct 21;12(1):549. doi: 10.1186/s13287-021-02615-z. Stem Cell Res Ther. 2021. PMID: 34674761 Free PMC article.
-
Standardized prehospital treatment of stroke.Dtsch Arztebl Int. 2011 Sep;108(36):585-91. doi: 10.3238/arztebl.2011.0585. Epub 2011 Sep 9. Dtsch Arztebl Int. 2011. PMID: 21966316 Free PMC article. Review.
-
Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.J Neurochem. 2010 Apr;113(2):303-12. doi: 10.1111/j.1471-4159.2010.06613.x. J Neurochem. 2010. PMID: 20405577 Free PMC article. Review.
References
-
- Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-pa stroke study group. N Engl J Med. 1995;333:1581–1587. - PubMed
-
- Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329. - PubMed
-
- Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: A randomized controlled trial. Alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. JAMA. 1999;282:2019–2026. - PubMed
-
- Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici M ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The european cooperative acute stroke study (ECASS) JAMA. 1995;274:1017–1025. - PubMed
-
- Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P Second European-Australian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) Lancet. 1998;352:1245–1251. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical